FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214651108> ?p ?o ?g. }

• W4214651108 endingPage "1069" @default.
• W4214651108 startingPage "1059" @default.
• W4214651108 abstract "Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes. However, the effects and risks of anti-thrombotics for this indication are unknown. We therefore aimed to assess the safety and efficacy of intravenous aspirin, unfractionated heparin, both, or neither started during endovascular treatment in patients with ischaemic stroke.We did an open-label, multicentre, randomised controlled trial with a 2 × 3 factorial design in 15 centres in the Netherlands. We enrolled adult patients (ie, ≥18 years) with ischaemic stroke due to an intracranial large-vessel occlusion in the anterior circulation in whom endovascular treatment could be initiated within 6 h of symptom onset. Eligible patients had a score of 2 or more on the National Institutes of Health Stroke Scale, and a CT or MRI ruling out intracranial haemorrhage. Randomisation was done using a web-based procedure with permuted blocks and stratified by centre. Patients were randomly assigned (1:1) to receive either periprocedural intravenous aspirin (300 mg bolus) or no aspirin, and randomly assigned (1:1:1) to receive moderate-dose unfractionated heparin (5000 IU bolus followed by 1250 IU/h for 6 h), low-dose unfractionated heparin (5000 IU bolus followed by 500 IU/h for 6 h), or no unfractionated heparin. The primary outcome was the score on the modified Rankin Scale at 90 days. Symptomatic intracranial haemorrhage was the main safety outcome. Analyses were based on intention to treat, and treatment effects were expressed as odds ratios (ORs) or common ORs, with adjustment for baseline prognostic factors. This trial is registered with the International Standard Randomised Controlled Trial Number, ISRCTN76741621.Between Jan 22, 2018, and Jan 27, 2021, we randomly assigned 663 patients; of whom, 628 (95%) provided deferred consent or died before consent could be asked and were included in the modified intention-to-treat population. On Feb 4, 2021, after unblinding and analysis of the data, the trial steering committee permanently stopped patient recruitment and the trial was stopped for safety concerns. The risk of symptomatic intracranial haemorrhage was higher in patients allocated to receive aspirin than in those not receiving aspirin (43 [14%] of 310 vs 23 [7%] of 318; adjusted OR 1·95 [95% CI 1·13-3·35]) as well as in patients allocated to receive unfractionated heparin than in those not receiving unfractionated heparin (44 [13%] of 332 vs 22 [7%] of 296; 1·98 [1·14-3·46]). Both aspirin (adjusted common OR 0·91 [95% CI 0·69-1·21]) and unfractionated heparin (0·81 [0·61-1·08]) led to a non-significant shift towards worse modified Rankin Scale scores.Periprocedural intravenous aspirin and unfractionated heparin during endovascular stroke treatment are both associated with an increased risk of symptomatic intracranial haemorrhage without evidence for a beneficial effect on functional outcome.The Collaboration for New Treatments of Acute Stroke consortium, the Brain Foundation Netherlands, the Ministry of Economic Affairs, Stryker, Medtronic, Cerenovus, and the Dutch Heart Foundation." @default.
• W4214651108 created "2022-03-02" @default.
• W4214651108 creator A5000075167 @default.
• W4214651108 creator A5000326139 @default.
• W4214651108 creator A5002846658 @default.
• W4214651108 creator A5004861719 @default.
• W4214651108 creator A5005344989 @default.
• W4214651108 creator A5005658006 @default.
• W4214651108 creator A5006225939 @default.
• W4214651108 creator A5007939735 @default.
• W4214651108 creator A5009172577 @default.
• W4214651108 creator A5010268705 @default.
• W4214651108 creator A5011874317 @default.
• W4214651108 creator A5014208730 @default.
• W4214651108 creator A5014957841 @default.
• W4214651108 creator A5017884714 @default.
• W4214651108 creator A5017929637 @default.
• W4214651108 creator A5019358630 @default.
• W4214651108 creator A5021331005 @default.
• W4214651108 creator A5021754055 @default.
• W4214651108 creator A5022751827 @default.
• W4214651108 creator A5023753895 @default.
• W4214651108 creator A5023767624 @default.
• W4214651108 creator A5024106604 @default.
• W4214651108 creator A5024309954 @default.
• W4214651108 creator A5024927727 @default.
• W4214651108 creator A5026314299 @default.
• W4214651108 creator A5026647662 @default.
• W4214651108 creator A5030705633 @default.
• W4214651108 creator A5036387722 @default.
• W4214651108 creator A5036799955 @default.
• W4214651108 creator A5038588602 @default.
• W4214651108 creator A5041039861 @default.
• W4214651108 creator A5041701048 @default.
• W4214651108 creator A5043499668 @default.
• W4214651108 creator A5044736064 @default.
• W4214651108 creator A5045958041 @default.
• W4214651108 creator A5046434206 @default.
• W4214651108 creator A5049064550 @default.
• W4214651108 creator A5049075389 @default.
• W4214651108 creator A5050307718 @default.
• W4214651108 creator A5050658147 @default.
• W4214651108 creator A5052180742 @default.
• W4214651108 creator A5053444039 @default.
• W4214651108 creator A5053748100 @default.
• W4214651108 creator A5055304531 @default.
• W4214651108 creator A5055637046 @default.
• W4214651108 creator A5056950596 @default.
• W4214651108 creator A5060241949 @default.
• W4214651108 creator A5062338618 @default.
• W4214651108 creator A5063013324 @default.
• W4214651108 creator A5063851108 @default.
• W4214651108 creator A5064307048 @default.
• W4214651108 creator A5067039906 @default.
• W4214651108 creator A5069603301 @default.
• W4214651108 creator A5074952767 @default.
• W4214651108 creator A5076335937 @default.
• W4214651108 creator A5079930755 @default.
• W4214651108 creator A5081542140 @default.
• W4214651108 creator A5082402914 @default.
• W4214651108 creator A5083203309 @default.
• W4214651108 creator A5084860153 @default.
• W4214651108 creator A5085305357 @default.
• W4214651108 creator A5086830720 @default.
• W4214651108 creator A5089033425 @default.
• W4214651108 date "2022-03-01" @default.
• W4214651108 modified "2023-10-15" @default.
• W4214651108 title "Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial" @default.
• W4214651108 cites W1965593262 @default.
• W4214651108 cites W2045819100 @default.
• W4214651108 cites W2051824928 @default.
• W4214651108 cites W2061638485 @default.
• W4214651108 cites W2084521665 @default.
• W4214651108 cites W2117855158 @default.
• W4214651108 cites W2133514192 @default.
• W4214651108 cites W2148173212 @default.
• W4214651108 cites W2153792869 @default.
• W4214651108 cites W2198398064 @default.
• W4214651108 cites W2273024126 @default.
• W4214651108 cites W2277258071 @default.
• W4214651108 cites W2297611545 @default.
• W4214651108 cites W2337062548 @default.
• W4214651108 cites W2509299184 @default.
• W4214651108 cites W2765874574 @default.
• W4214651108 cites W2800285152 @default.
• W4214651108 cites W2810048104 @default.
• W4214651108 cites W2911196419 @default.
• W4214651108 cites W2926247356 @default.
• W4214651108 cites W2946975851 @default.
• W4214651108 cites W2960982617 @default.
• W4214651108 cites W3043456764 @default.
• W4214651108 cites W3094627673 @default.
• W4214651108 cites W3132060044 @default.
• W4214651108 cites W4226441491 @default.
• W4214651108 doi "https://doi.org/10.1016/s0140-6736(22)00014-9" @default.
• W4214651108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35240044" @default.
• W4214651108 hasPublicationYear "2022" @default.
• W4214651108 type Work @default.

• next